Information needs among patients and a surveillance strategy after surgery for pancreatic and periampullary cancer  by Labori, Knut J. et al.
LETTER TO THE EDITOR
Information needs among patients and a surveillance strategy after
surgery for pancreatic and periampullary cancer
Recommendations for surveillance after resection of pancreatic
and periampullary cancer are based on low-level evidence.1
There is no consensus on the optimal follow-up. Ultimately,
the decision regarding the intensiveness of follow-up is left to
the discretion of the treating physician after discussion with
the patient. Accordingly, the study by Deobald et al.2 on the
attitude of patients and clinicians towards surveillance after a
resection for pancreatic (n = 10) or periampullary (n = 5) can-
cer is highly appreciated. A question that needs to be raised,
however, is whether, in this study, the lack of a distinction
between pancreatic and periampullary cancer may have
resulted in obfuscation of key prognostic information. There is
a significant difference in the outcome between pancreatic, bile
duct, ampullary and duodenal cancer.3 The information pro-
vided by the clinicians is guided by pathology-based tumour
characteristics (cancer origin, intestinal or pancreatobiliary
subtype, grade, resection margin and lymph node status).3
Currently, adjuvant treatment is recommended only for pan-
creatic adenocarcinoma. Furthermore, NCCN guidelines state
that surveillance of pancreatic adenocarcinoma is based on the
consensus that earlier detection of recurrence may facilitate
patient recruitment to investigational treatment studies.1
Cancer origin is invariably a criterion for patient eligibility for
clinical trials. Interestingly, two observational studies on sys-
tematic CT-based follow-up after potentially curative resection
for pancreatic adenocarcinoma showed that patients with
asymptomatic recurrence had improved survival and received
oncological treatment more frequently.4,5 The detection of
asymptomatic recurrence might be even more important in
patients with often less aggressive periampullary tumours such
as ampullary and duodenal adenocarcinoma.
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